MetaCap

Arbutus Biopharma (ABUS) vs Janux Therapeutics (JANX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Arbutus Biopharma (ABUS) has outperformed Janux Therapeutics (JANX) over the past year, losing 6.7% versus a loss of 65.0%. Over five years, ABUS leads with a +28.4% price change compared with -42.9% for JANX. Janux Therapeutics is the larger company by market cap ($616.7 million vs $616.2 million), about 1.0 times the size, while Arbutus Biopharma is growing revenue faster (+128.2% vs -5.6%).

Arbutus Biopharma converts more of its revenue into profit, with a net margin of -237.9% versus -1136.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABUS-6.73%JANX-65.00%
+25%-22%-69%
Nov 21, 20251 yearNov 20, 2026
ABUS+21.82%JANX-43.62%
+280%+99%-83%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABUS versus JANX key metrics
MetricABUSJANX
Share price$4.02$10.08
Market cap$616.24M$616.73M
1-day change-1.23%-2.04%
YTD return-16.42%-26.96%
1-year return-6.73%-65.00%
5-year return+28.43%-42.92%
P/E ratio (TTM)3.59—
EPS (TTM)$1.12$-1.59
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$14.08M$10.00M
Revenue growth (YoY)+128.21%-5.55%
Net income (latest FY)$-33.50M$-113.63M
Operating margin-270.96%-1576.67%
Net margin-237.88%-1136.25%
52-week high$5.45$35.34
52-week low$3.50$10.05
Distance from 52-week high-26.24%-71.48%
Analyst consensusnonestrong_buy
Avg. price target upside+32.34%+228.77%
Average volume4.98M961.56K
Shares outstanding153.29M61.18M
Employees19114
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ABUS has outperformed JANX by 58.3 percentage points over the past year.
  • Arbutus Biopharma is more profitable, keeping -237.9 cents of every revenue dollar as net income versus -1136.3 cents for Janux Therapeutics.
  • Arbutus Biopharma grew revenue faster in its latest fiscal year (+128.21% vs -5.55%).

About Arbutus Biopharma

ABUS stock →

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.

Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees

About Janux Therapeutics

JANX stock →

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 114 employees

ABUS vs JANX FAQ

Which is bigger, Arbutus Biopharma or Janux Therapeutics?

Janux Therapeutics (JANX) is larger, with a market capitalization of $616.73M compared with $616.24M for Arbutus Biopharma (ABUS).

Which stock has performed better over the past year, ABUS or JANX?

ABUS returned -6.73% over the past 12 months, compared with -65.00% for JANX (price return, excluding dividends). Past performance does not predict future results.

Are Arbutus Biopharma and Janux Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons